A randomized phase II/III study of 'novel therapeutics' versus azacitidine in newly diagnosed patients with acute myeloid leukemia (AML), high-risk myelodysplastic syndrome (MDS), or chronic myelomonocytic leukemia (CMML), age 60 or older: a report of the comparison of azacitidine and nivolumab to azacitidine: SWOG S1612.
Sarit AssoulineLaura C MichaelisMegan OthusAnnette E HayRoland B WalterMeagan A JacobyMark A SchroederGeoffrey L UyLisa Y LawFaisal CheemaKendra L SweetAdam S AschJijun Jane LiuAnna B MoseleyTracy MaherLaura L KingsburyMin FangJerald RadichRichard F LittleHarry P ErbaPublished in: Leukemia & lymphoma (2022)